Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction
Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction
复制标题
DOI：
10.1111/1471-0528.12522
复制
发表时间：
2014-04-01
影响因子：
5.8
通讯作者：
Johansen, M.
中科院分区：
文献类型：
--
作者：
Ersboll, A. S.;Hedegaard, M.;Johansen, M.
目的探讨先天性或获得性心脏病孕妇在妊娠期间口服β受体阻滞剂治疗对胎儿生长的影响。设计历史配对队列研究。丹麦哥本哈根大学医院孕妇心脏病中心。人口175名心脏病妇女的队列，根据β受体阻滞剂治疗分组，和一个队列的627名妇女从整体人口匹配的7个出生体重决定factors.MethodsDifferences组之间进行了测试，简单的描述性统计和评估使用标准的假设检验。主要结果测量小于胎龄儿（SGA）的比例。结果暴露于β受体阻滞剂的婴儿中小于胎龄儿的比例高于未暴露的婴儿（29.4%比15.3%; P
ObjectiveTo investigate the effect on fetal growth of treatment with oral beta-blockers during pregnancy in women with congenital or acquired heart disease.DesignHistorical matched cohort study.SettingCentre for Pregnant Women with Heart Disease, Copenhagen University Hospital, Denmark.PopulationA cohort of 175 women with heart disease, grouped according to beta-blocker treatment, and a cohort of 627 women from the overall population matched on seven birthweight-determining factors.MethodsDifferences between groups were tested by simple descriptive statistics and assessed using standard hypothesis tests. Associations were estimated by correlational analysis and multivariable regression.Main outcome measureProportion of infants born small for gestational age (SGA).ResultsMore of the infants exposed to beta-blockers were SGA compared with non-exposed infants (29.4 versus 15.3%; P